Agomelatine (Valdoxan): Depression, Liver Tests and Stopping Treatment

Valdoxan contains agomelatine and is authorized for major depressive episodes in adults. It acts at melatonin receptors and blocks a serotonin receptor called 5-HT2C. Its mechanism differs from serotonin reuptake inhibition. [1] That pharmacological distinction can inform a prescribing discussion, but it does not identify the best medicine for an individual by itself.

Ask your clinician which symptoms and daily difficulties the treatment is meant to improve. Describe mood, loss of interest, sleep, motivation and functioning separately. A change in one area is useful information without being proof that every part of a depressive episode has resolved. Clarify the plan for psychotherapy, practical support or other care alongside the prescription.

The medicine’s activity at melatonin receptors helps explain why sleep patterns may be discussed during treatment. Its authorized purpose remains depression, rather than being an interchangeable version of melatonin or an ordinary sleeping tablet. [1]

For a review, describe when you sleep, how often you wake, whether mornings are difficult and what daytime functioning is like. Keep these observations separate from mood. Ask whether the treatment goal is a more regular routine, relief of the depressive episode, or both, and how the team will assess progress.

Do not compare tablets by whether they make you feel immediately sleepy. Ask for an explanation of any proposed treatment change in terms of the diagnosis and goals. If sleep remains poor, describe the pattern rather than adding another sedating medicine without checking the combination.

In a randomized study, people who had responded to an initial course of agomelatine were less likely to relapse when they continued treatment than when they switched to placebo over the following six months. The study concerns selected responders, not everyone beginning treatment. [4]

A separate report comparing two relapse-prevention studies explains why the results were not identical. One trial had an unexpectedly low placebo relapse rate and could not demonstrate a clear overall treatment separation. Patient selection and study design affected interpretation. [5] A single favorable trial should therefore not be presented as a guarantee of long-term stability.

Ask what the evidence means for your own review: which benefits have occurred, which remain uncertain, and what would lead to continuation or a change. Bring both the wish to preserve improvement and any concern about ongoing monitoring. These are parts of the same benefit-risk discussion.

UK safety guidance requires liver blood tests before treatment and at approximately three, six, twelve and twenty-four weeks, with further testing when clinically indicated. Monitoring is also needed after a dose increase. Symptoms alone do not replace these checks. [2]

Before starting, confirm who orders the tests, who reviews the results and how you will be contacted. Put the appointments in a form you can access when traveling or changing clinicians. Ask what to do when a test is delayed or missed rather than assuming that no news means everything is satisfactory.

Keep the monitoring discussion practical. Can the required tests be arranged where you will be living? Does the next prescriber have the previous results? Which service is responsible during a handover? The prescription and the monitoring arrangements should move together, rather than leaving one team to assume that another has taken responsibility.

Dark urine, pale stools, yellow skin or eyes, upper-right abdominal pain, or sustained unexplained new tiredness can indicate liver injury. Regulatory advice is to stop agomelatine and obtain urgent medical advice when these symptoms appear. Do not wait for the next scheduled blood test. [3]

This is not the same situation as deciding to stop because you feel better. Tell the assessing clinician the medicine name, when treatment began and any recent change. Bring available results and a medicine list when possible, without delaying care to find them.

Ask the team how the mental-health plan will be maintained if treatment must be interrupted for safety. Once an urgent problem has been assessed, the next steps should explain both the physical-health follow-up and support for depression. Do not restart a stopped medicine independently because the symptom seems to have settled.

Agomelatine must not be used with active liver disease or cirrhosis, or when liver enzymes exceed the specified threshold. The product information advises against use from age seventy-five and does not establish routine treatment for depression in people under eighteen. Kidney impairment, a history of mania and pregnancy-related questions need individual assessment. [6]

Bring relevant health history to the appointment even when it seems unrelated to mood. Include prior abnormal liver tests, previous reactions to antidepressants and any periods of unusually elevated energy with little need for sleep. Ask which findings affect suitability and which affect monitoring.

Discuss pregnancy plans and breastfeeding before making a routine change. A useful conversation compares the possible risks of treatment with the risks of an untreated depressive episode, while recognizing uncertainty. Ask how advice from the mental-health clinician will be coordinated with maternity or primary-care services.

Fluvoxamine and ciprofloxacin are important contraindicated combinations because they can greatly affect agomelatine exposure. Other medicines that affect liver function or drug metabolism also warrant review. [6]

Tell another clinician or dentist that you take agomelatine before they issue a prescription. A short antibiotic course should not be assumed irrelevant to an established antidepressant. Ask the pharmacist to check the whole list, including supplements and medicines taken only occasionally.

Record changes in smoking as part of the history discussed with the prescriber, since the product information identifies smoking-related changes in exposure. [6] This is a reason to coordinate a cessation plan and medication review, not a reason to keep smoking or alter agomelatine yourself.

Substantial alcohol intake and alcohol-use disorder are among the liver-risk factors requiring particular consideration. Regulatory guidance also highlights obesity, fatty liver disease, diabetes and other potentially liver-affecting medicines. [2]

Explain drinking patterns openly, including use for sleep or emotional relief. Ask how depression treatment and alcohol-related care will be coordinated. An agomelatine prescription is not an acute alcohol-withdrawal plan. Its documented adult indication is depression, not detoxification. [1]

Prepare a timeline of mood symptoms, alcohol use, previous reductions and medication changes. Ask which team will manage each concern and what setting is appropriate for assessment. The co-occurring-needs overview describes the broader context without implying that every reader needs residential care.

Headache, nausea and dizziness are among the common reported effects. [1] The patient leaflet also describes sleepiness, sleep disturbances and other possible reactions; driving should be avoided when alertness is impaired. [7]

Describe a symptom through its effect on daily life: difficulty working, missing meals, unsteadiness or being unable to follow a usual routine. Note when it began and any change in other treatment. Ask what can be reviewed routinely and what needs earlier contact. Do not classify the liver-warning symptoms above as ordinary tiredness or stomach upset without assessment.

New suicidal thoughts or a marked change in mood or behavior require prompt help; use emergency services when there is immediate danger. [7] An agreed contact plan should remain usable between appointments, especially during the early treatment period.

The product information states that agomelatine itself does not require a dosage taper at discontinuation. That does not remove the need to agree why treatment is ending and how depression will be followed. Withdrawal from a previous SSRI or SNRI can still occur during a switch and needs its own plan. [6]

This distinction matters when symptoms appear after several medicines have changed close together. Write down what changed and when, rather than assuming that the newest tablet explains everything. Ask the clinician to identify which medicine any reduction instructions concern.

For a non-urgent stopping discussion, bring the benefits you value, the difficulties you want addressed and the support available afterward. For suspected liver injury, follow urgent safety advice rather than delaying action until a routine stopping appointment. These situations need different responses.

Is agomelatine just prescription melatonin?

No. It has a distinct antidepressant mechanism and monitoring requirements. Its relationship to melatonin receptors does not make it interchangeable with a sleep supplement. [1]

Can normal liver tests once replace later monitoring?

No. The safety plan includes repeated testing during treatment and after relevant changes. Confirm the next appointment and who reviews the result. [2]

What should I bring to a review?

Bring the medicine packet, liver-test dates and results, a complete treatment list and notes about mood and sleep. The medication-review checklist can help organize the conversation.

1. EMA: Valdoxan overview.
2. MHRA: Liver risk and monitoring.
3. MHRA: Advice on symptoms of liver injury.
4. Randomized relapse-prevention trial.
5. Comparison of two relapse-prevention studies.
6. Servier: Valdoxan product information.
7. Valdoxan patient leaflet.

Availability and prescribing arrangements differ by country. Inclusion in the medication library does not establish a COGNIFUL prescribing service.